1
|
Süren D, Yildirim M, Sayiner A, Alikanoğlu AS, Atalay I, Gündüz UR, Kaya V, Gündüz Ş, Oruç MT, Sezer C. Expression of claudin 1, 4 and 7 in thyroid neoplasms. Oncol Lett 2017; 13:3722-3726. [PMID: 28529587 DOI: 10.3892/ol.2017.5916] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 01/06/2017] [Indexed: 01/28/2023] Open
Abstract
The distinction of thyroid carcinoma from benign thyroid neoplasm, as well as the subtyping of papillary carcinoma (PC) and follicular carcinoma (FC), may be performed histopathologically in the majority of cases. However, in certain cases, it is difficult to histopathologically distinguish between PC and FC, as well as follicular adenoma (FA), FC and the dominant nodule of multinodular goiter (MNG-DN). The present study aimed to determine the roles of the expression levels of the tight junction proteins claudin 1, 4 and 7 in the differential diagnosis of PC, FC, FA, MNG-DN, medullary carcinoma (MC) and anaplastic carcinoma (AC). The current study included 114 cases of histopathologically diagnosed thyroid neoplasia, which were distributed as follows: 29 FA, 18 MNG-DN, 47 PC, 10 FC, 5 MC and 5 AC. The expression levels of claudin 1, 4 and 7 were examined using immunohistochemical methods. The results revealed a significant difference in claudin 1 expression between malignant and benign thyroid neoplasms (P<0.001). Claudin 1 expression was not detected in any of the MNG-DN cases, and no significant difference in claudin 1 expression levels was identified between FA and FC (P=0.653). However, a statistically significant difference was observed between FC and PC (P<0.001). Claudin 4 expression did not differ between malignant and benign thyroid neoplasms, neither between MNG-DN, FA and FC, nor between FC and PC (P=0.068, P=0.502 and P=0.481, respectively). Claudin 7 exhibited positive immunohistochemical staining in 107 patients (94%); however, no significant difference in claudin 7 expression §levels was identified between malignant and benign thyroid neoplasms among MNG-DN, FA and FC (malignant, P=0.135; benign, P=0.470). Claudin 7 exhibited positive staining in all PC and FC cases. Therefore, claudin 1 expression levels may be useful in distinguishing cases of FC and PC with overlapping histopathological features, and provide a novel immunohistochemical marker for the subtyping of thyroid carcinoma.
Collapse
Affiliation(s)
- Dinç Süren
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Mustafa Yildirim
- Department of Medical Oncology, Medical Park Hospital, Gaziantep 27100, Turkey
| | - Alper Sayiner
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Arsenal Sezgin Alikanoğlu
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Irem Atalay
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Umut Riza Gündüz
- Department of General Surgery, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Vildan Kaya
- Department of Radiation Oncology, Süleyman Demirel University, Isparta 32260, Turkey
| | - Şeyda Gündüz
- Department of Medical Oncology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Mehmet Tahir Oruç
- Department of General Surgery, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| | - Cem Sezer
- Department of Pathology, University of Health Sciences, Antalya Education and Research Hospital, Antalya 07050, Turkey
| |
Collapse
|
2
|
Gündüz UR, Gunaldi M, Isiksacan N, Gündüz S, Okuturlar Y, Kocoglu H. A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study. Mol Clin Oncol 2016; 5:355-360. [PMID: 27446579 DOI: 10.3892/mco.2016.919] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Accepted: 05/09/2016] [Indexed: 01/17/2023] Open
Abstract
Breast cancer is the most frequently diagnosed cancer type in women. Tumor markers have been widely used for assessing the treatment response and early diagnosis of recurrence. Human epididymis protein 4 (HE4) is expressed in ductal carcinoma of the breast tissue; however, its serum levels and their diagnostic and prognostic potential in breast cancer have not been investigated, which was therefore the aim of the present study. The serum levels of HE4 were determined in 36 breast cancer patients, 11 ovarian cancer patients and 16 healthy volunteers. The association between clinicopathological characteristics of breast cancer and serum HE4 levels was investigated. A significant difference in the median serum levels of HE4 was identified between breast cancer patients, ovarian cancer patients and healthy volunteers (P=0.013). The cutoff value for the prediction of breast cancer was determined at >13.24 pmol/l for HE4, with a sensitivity of 61.11%, specificity of 68.75%, positive predictive value of 81.48%, negative predictive value of 44.0% and accuracy of 63.46%. Furthermore, a positive correlation between the serum levels of HE4 and cancer antigen 15-3 was determined (r=0.399, P=0.026). To the best of our knowledge, the present study was the first to determine the diagnostic value of serum HE4 for breast cancer. A significant elevation of serum HE4 levels in patients with breast cancer compared with that in healthy controls was identified. HE4 may serve as a novel biomarker for the diagnosis of breast cancer.
Collapse
Affiliation(s)
- Umut Riza Gündüz
- Department of General Surgery, Antalya Education and Research Hospital, Antalya 07100, Turkey
| | - Meral Gunaldi
- Department of Medical Oncology, Bakırköy Education and Research Hospital, Istanbul 07100, Turkey
| | - Nilgun Isiksacan
- Department of Biochemistry, Bakırköy Education and Research Hospital, Istanbul 07100, Turkey
| | - Seyda Gündüz
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya 07100, Turkey
| | - Yildiz Okuturlar
- Department of Internal Medicine, Bakırköy Education and Research Hospital, Istanbul 34147, Turkey
| | - Hakan Kocoglu
- Department of Internal Medicine, Bakırköy Education and Research Hospital, Istanbul 34147, Turkey
| |
Collapse
|
3
|
Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol Clin Oncol 2015; 3:1109-1112. [PMID: 26623060 DOI: 10.3892/mco.2015.610] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2014] [Accepted: 03/31/2015] [Indexed: 01/03/2023] Open
Abstract
Breast cancer is the most frequently diagnosed cancer in women worldwide and the second cause of cancer-related mortality. A total of 20-30% of patients with early-stage breast cancer develop recurrence within the first 5 years following diagnosis. Trastuzumab significantly improves overall survival and disease-free survival (DFS) in women with human epidermal growth factor receptor 2 (HER2)-positive early and locally advanced breast cancer. This study aimed to determine the factors that affect DFS following adjuvant transtuzumab therapy. A total of 62 patients treated with trastuzumab for early and locally advanced breast cancer were included in our study. Data, including pathology, treatment and treatment outcome, rate of recurrence and laboratory tests, were retrospectively collected. There was no significant association between DFS and age, menopausal status, disease stage and hormone receptor status. The median follow-up was 48.4 months. The median DFS of patients treated with adjuvant trastuzumab was 64.1 months. In addition, the median DFS was 44.3 vs. 66.8 months in patients with platelet-lymphocyte ratio (PLR) ≤200 vs. >200, respectively (log-rank test; P=0.001), and 70 vs. 45 months in patients with eosinophil count ≤70 vs. >70×103/mm3 (log-rank test; P=0.001). Our data revealed the prognostic relevance of a decrease in the peripheral blood eosinophil count and PLR value following trastuzumab therapy in breast cancer. PLR and eosinophil count measurements are cost-effective, readily available worldwide, non-invasive and safe. Combined with other markers, such as patient age, tumor stage and tumor histology, may be effectively used for patients with breast cancer.
Collapse
Affiliation(s)
- Seyda Gündüz
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Deniz Arslan
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Ali Murat Tatli
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Mükremin Uysal
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Umut Riza Gündüz
- Department of Surgery, Antalya Research and Training Hospital, Antalya 07070, Turkey
| | - Mert Mahsuni Sevinç
- Department of Surgery, Istanbul Research and Training Hospital, Istanbul 34000, Turkey
| | - Hasan Senol Coşkun
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Hakan Bozcuk
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| | - Burhan Savas
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey
| |
Collapse
|
4
|
Karakaş BR, Aslaner A, Gündüz UR, Çalış H, Öngen AN, Öner OZ, Bülbüller N. Erratum to: is the lateralization distance important in terms in patients undergoing the modified Limberg flap procedure for treatment of pilonidal sinus? Tech Coloproctol 2015; 19:197. [PMID: 25616915 DOI: 10.1007/s10151-014-1262-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- B R Karakaş
- Department of General Surgery, Antalya Training and Research Hospital, Antalya, 07100, Turkey,
| | | | | | | | | | | | | |
Collapse
|